FDA Issues Draft Guidance on Compounding Animal Drugs

The FDA published draft guidance expanding enforcement discretion for compounding animal drugs from bulk drug substances to include federally-registered drug manufacturing facilities and outsourcing facilities, while maintaining CGMP compliance requirements. The guidance seeks to balance animal treatment needs with safety and regulatory obligations and invites public comment until November 27, 2026.

This Wire brief sits within Fusion42's coverage of Health.